Gardembas, Martine
Centre Léon Bérard · Centre Hospitalier Universitaire d'Angers
5 papers on CoChatORCID 0000-0003-3687-0932
Most cited papers
- Verified
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Gardembas, M., Etienne, G., Réa, D., Roy, L., et al. (2014) · Journal of Clinical Oncology
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 416
- Verified
Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients
Nicolini, F. E., Dulucq, S., Boureau, L., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Rigal-Huguet, F., Coiteux, V., Varet, B., Dubruille, V., et al. (2019) · Clinical Cancer Research
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 111
- Verified
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
Rousselot, P., Mollica, L., Guilhot, J., Guerci, A., Nicolini, F. E., Etienne, G., Legros, L., Charbonnier, A., Coiteux, V., Dartigeas, C., et al. (2021) · British Journal of Haematology
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 46
- Verified
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐ STIM study
Dulucq, S., Rigal‐Huguet, F., Nicolini, F. E., Cony‐Makhoul, P., Escoffre‐Barbe, M., Gardembas, M., Legros, L., Rousselot, P., Liu, J., Rea, D., et al. (2023) · British Journal of Haematology
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 22
- Verified
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
Dulucq, S., Nicolini, F. E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., et al. (2022) · Haematologica
Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free